Registration Strip Icon for default 무료로 등록하여 실시간 주식 시세, 대화형 차트, 실시간 옵션 플로우 등을 받아보세요.

IGC

IGC Pharma (IGC)

IGC Pharma Inc
일자:
정렬 기준:
 검색 관련기사 보기:AMEX:IGC
일자시간출처헤드라인심볼기업
2024/04/1620:00Business WireIGC-AD1’s Interim Phase 2 Data Show a Reduction in Alzheimer’s Agitation at Week TwoAMEX:IGCIGC Pharma Inc
2024/04/0922:00Business WireIGC Pharma Adds Advisor in Artificial IntelligenceAMEX:IGCIGC Pharma Inc
2024/03/2704:00Business WireIGC Pharma Announces $3 Million Unregistered Private Placement of its Common StockAMEX:IGCIGC Pharma Inc
2024/03/2100:00Business WireIGC Pharma Announces Positive Interim Results for IGC-AD1 in Reducing Alzheimer’s AgitationAMEX:IGCIGC Pharma Inc
2024/03/2020:00Business WireIGC PHARMA Announces its Participation at the Benzinga Virtual Healthcare Summit 2024AMEX:IGCIGC Pharma Inc
2024/03/1304:00Business WireIGC Pharma (IGC): Healthcare Leader Terry Lierman Joins Board to Advance Alzheimer’s PipelineAMEX:IGCIGC Pharma Inc
2024/02/2903:00Business WirePromising Results: TGR-63 Enhances Memory in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
2024/02/2402:01Business WireIGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price TargetAMEX:IGCIGC Pharma Inc
2024/02/1709:05Business WireIGC Pharma Reports Third Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
2024/02/1506:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
2024/02/0123:20Business WireIGC Pharma Announces TGR-63 Reduces Agitation in Alzheimer's Mouse ModelAMEX:IGCIGC Pharma Inc
2024/02/0106:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
2024/01/2323:20Business WireIGC Pharma Breakthrough: Preclinical Trial Data Shows TGR-63 Reduces Plaque in Alzheimer’sAMEX:IGCIGC Pharma Inc
2024/01/1723:20Business WireIGC Pharma Activates ClinCloud, One of 12 Sites in Ongoing Phase 2b Alzheimer’s TrialAMEX:IGCIGC Pharma Inc
2024/01/0914:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
2023/12/3006:54Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
2023/12/1923:20Business WirePatent Granted to IGC Pharma for Groundbreaking Drug Formulation to Treat Agitation in Alzheimer’sAMEX:IGCIGC Pharma Inc
2023/12/1323:30Business WireIGC Pharma Announces Participation in Biotech Showcase and BioPartnering @ JPM Alongside the J.P. Morgan 41st Annual Healthcare Conference 2024AMEX:IGCIGC Pharma Inc
2023/12/0622:30Business WireIGC Pharma Announces Collaboration to Integrate AI into Clinical TrialsAMEX:IGCIGC Pharma Inc
2023/11/2122:30Business WireIGC Pharma Announces Master Agreement with Leading South American University to Advance AI InitiativesAMEX:IGCIGC Pharma Inc
2023/11/1322:00Business WireIGC Pharma Reports Second Quarter Fiscal 2024 ResultsAMEX:IGCIGC Pharma Inc
2023/11/1007:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:IGCIGC Pharma Inc
2023/10/2806:21Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
2023/10/2805:38Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:IGCIGC Pharma Inc
2023/10/2004:30Business WireIGC Pharma Granted European Patent for Groundbreaking Cannabinoid-Based Pain Topical Relief TherapyAMEX:IGCIGC Pharma Inc
2023/10/0613:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:IGCIGC Pharma Inc
2023/09/3006:23Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933AMEX:IGCIGC Pharma Inc
2023/08/2203:30Business WireIGC Announces Results of its 2023 Annual Stockholders MeetingAMEX:IGCIGC Pharma Inc
2023/08/2201:44Edgar (US Regulatory)Form 8-K - Current reportAMEX:IGCIGC Pharma Inc
2023/08/1421:30Business WireIGC Pharma Reports First Quarter Results; Company Continues to Make Significant Progress Advancing Its Lead Alzheimer’s Candidate Through Phase 2 Clinical TrialsAMEX:IGCIGC Pharma Inc
 검색 관련기사 보기:AMEX:IGC